Amgen sales rose by 5% in Q1

Share this article:

First-quarter Kyprolis sales of $68 million helped increase Amgen's first-quarter sales by 5% compared to the same period last year.

While the biotech saw increased demand and sales for drugs, including bone biologic Prolia and anemia product Epogen, demand and sales declined for some brands, with sales of RA shot Enbrel slipping 5% and kidney drug Aranesp sales falling 2% compared to the same period last year. The company attributed some of this fall-off to inventory draw-down.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.